Inogen (NASDAQ:INGN) Earns “Hold” Rating from Needham & Company LLC

Needham & Company LLC restated their hold rating on shares of Inogen (NASDAQ:INGN) in a research note issued to investors on Tuesday morning, Benzinga reports.

Separately, William Blair upgraded shares of Inogen from a market perform rating to an outperform rating in a research report on Thursday, February 15th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and one has given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of Hold and an average price target of $13.67.

Inogen Price Performance

NASDAQ INGN opened at $7.28 on Tuesday. Inogen has a 1 year low of $4.13 and a 1 year high of $14.10. The stock has a market capitalization of $169.84 million, a PE ratio of -1.65 and a beta of 1.06. The company’s 50 day simple moving average is $7.67 and its two-hundred day simple moving average is $6.22.

Inogen (NASDAQ:INGN) last posted its earnings results on Tuesday, February 27th. The medical technology company reported ($1.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.65) by ($0.49). Inogen had a negative return on equity of 38.98% and a negative net margin of 32.46%. The firm had revenue of $75.90 million during the quarter, compared to analysts’ expectations of $78.09 million. On average, research analysts anticipate that Inogen will post -2.56 EPS for the current year.

Institutional Trading of Inogen

Institutional investors and hedge funds have recently made changes to their positions in the stock. Advisor Group Holdings Inc. raised its position in Inogen by 3,054.2% in the 1st quarter. Advisor Group Holdings Inc. now owns 3,722 shares of the medical technology company’s stock worth $119,000 after purchasing an additional 3,604 shares during the period. Bank of New York Mellon Corp raised its position in Inogen by 1.0% in the 1st quarter. Bank of New York Mellon Corp now owns 181,133 shares of the medical technology company’s stock worth $5,871,000 after purchasing an additional 1,836 shares during the period. US Bancorp DE raised its position in Inogen by 273.0% in the 1st quarter. US Bancorp DE now owns 884 shares of the medical technology company’s stock worth $28,000 after purchasing an additional 647 shares during the period. MetLife Investment Management LLC raised its position in Inogen by 66.5% in the 1st quarter. MetLife Investment Management LLC now owns 11,211 shares of the medical technology company’s stock worth $363,000 after purchasing an additional 4,479 shares during the period. Finally, Rhumbline Advisers raised its position in Inogen by 4.7% in the 1st quarter. Rhumbline Advisers now owns 54,415 shares of the medical technology company’s stock worth $1,764,000 after purchasing an additional 2,421 shares during the period. Hedge funds and other institutional investors own 89.94% of the company’s stock.

About Inogen

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.